Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5004 drug-drug interaction study with statins, repaglinide, and erythromycin
NCT06948747Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elecoglipron (3 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration time curve from time 0 to infinity, Area under concentration curve from time 0 to the last quantifiable concentration and 7 more. Started May 2025; status: completed.
02
Drugs
elecoglipron
Beyond the preview
Go deeper on NCT06948747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948747.